Product development in the life sciences sector is frequently complex, costly, and time-consuming, and collaborations between companies are common. Disputes may arise at all stages of development and commercialization. Our experience helps clients navigate disputes involving drug development and commercialization and identify relevant commercial factors (size of the opportunity, therapeutic area, business risks, etc.). CRA has provided expert reports and testimony evaluating development and commercialization efforts and assessing damages associated with alleged contractual breaches.
- 01CRA addressed a claim that a company had improperly failed to pay required development milestones upon termination of a drug development programIn litigation before the Delaware Court of Chancery, a CRA expert was asked to address the basis for a company’s decision to terminate the development of a...View engagement
- 02AAA arbitration regarding a collaboration and license agreementCRA provided expert reports and testimony on behalf of the respondent in an AAA arbitration concerning a collaboration and license agreement. It was alleged...View engagement
- 03Breach of contract damages analysis and testimonyCRA was retained by a leading national research university in a breach of contract dispute with a licensee of certain university patent rights related to a...View engagement